Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own1.00% Shs Outstand172.35M Perf Week-4.54%
Market Cap26.15B Forward P/E- EPS next Y-0.90 Insider Trans-64.78% Shs Float171.82M Perf Month3.90%
Income-313.70M PEG- EPS next Q-0.62 Inst Own96.10% Short Float2.64% Perf Quarter35.02%
Sales956.00M P/S27.35 EPS this Y32.10% Inst Trans0.53% Short Ratio3.29 Perf Half Y26.55%
Book/sh10.24 P/B14.82 EPS next Y63.90% ROA-15.80% Target Price145.50 Perf Year119.45%
Cash/sh4.64 P/C32.73 EPS next 5Y- ROE-18.70% 52W Range63.02 - 168.10 Perf YTD32.79%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-11.80% 52W High-9.74% Beta1.40
Dividend %- Quick Ratio4.20 Sales past 5Y26.20% Gross Margin93.40% 52W Low140.76% ATR6.70
Employees1605 Current Ratio4.50 Sales Q/Q20.10% Oper. Margin-29.20% RSI (14)52.63 Volatility3.40% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-32.80% Rel Volume2.53 Prev Close151.73
ShortableYes LT Debt/Eq0.00 EarningsApr 30 AMC Payout- Avg Volume1.38M Price151.73
Recom2.20 SMA20-2.29% SMA5013.47% SMA20039.45% Volume0 Change0.00%
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Jul-17-19Upgrade Piper Jaffray Neutral → Overweight $64 → $75
Apr-11-19Initiated Stifel Hold $70
Mar-27-19Initiated Berenberg Buy $95
Oct-26-18Reiterated Barclays Overweight $95 → $90
May-22-20 07:00PM  Anterix and Bausch Holding See Activist Action Barrons.com
May-19-20 01:02PM  Charting a headline breakout attempt, S&P 500 nails major resistance (2,954) MarketWatch
May-15-20 10:24PM  Edited Transcript of SGEN earnings conference call or presentation 30-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
01:20PM  Seattle Genetics' Adcetris Label Expands in EU for Lymphoma Zacks
11:20AM  Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners Zacks
May-14-20 08:00AM  Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma Business Wire
May-13-20 05:12PM  Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting Business Wire
May-12-20 08:00AM  Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer Business Wire
May-09-20 02:19PM  The Nasdaq is now up for the year here are the indexs best-performing stocks MarketWatch
May-08-20 10:39AM  Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected Zacks
May-07-20 05:42PM  Analysts See Seattle Genetics Profitable in 2022 GuruFocus.com
May-06-20 11:34AM  Industry Analysts Just Upgraded Their Seattle Genetics, Inc. (NASDAQ:SGEN) Revenue Forecasts By 10% Simply Wall St.
May-05-20 08:00AM  Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020 Business Wire +6.21%
May-04-20 01:25PM  Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales Zacks +6.95%
11:45AM  Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock TheStreet.com
May-01-20 02:30PM  Seattle Genetics Inc (SGEN) Q1 2020 Earnings Call Transcript Motley Fool +6.13%
Apr-30-20 05:15PM  Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:02PM  Seattle Genetics Reports First Quarter 2020 Financial Results Business Wire
11:12AM  Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat Zacks
Apr-29-20 12:00PM  Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy Zacks
10:05AM  Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More Zacks
Apr-28-20 12:11PM  Will Seattle Genetics Continue to Surge Higher? Zacks
Apr-24-20 08:00AM  Seattle Genetics Announces Change to Virtual Format for 2020 Annual Meeting Business Wire
Apr-23-20 12:32PM  Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-22-20 02:20PM  Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug MarketWatch
10:00AM  Seattle Genetics (NASDAQ:SGEN) Is In A Strong Position To Grow Its Business Simply Wall St.
Apr-21-20 12:34PM  With FDA Approvals in Hand, These 2 Biotech Stocks Are on Wall Streets Radar TipRanks
Apr-20-20 11:42AM  Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug Zacks
07:21AM  Seattle Genetics Breast Cancer Drug Approved Months Ahead of Schedule SmarterAnalyst
Apr-17-20 02:46PM  Seattle Genetics' stock rises on early FDA nod for breast-cancer drug MarketWatch
02:27PM  Seattle Genetics Announces U.S. FDA Approval of TUKYSA (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Business Wire
02:08PM  Seattle Genetics wins early U.S. approval for $18,500 breast cancer therapy Reuters
Apr-16-20 04:38PM  These Highly Rated Medical Stocks Broke Out Under Coronavirus Limelight Investor's Business Daily +6.69%
Apr-13-20 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2020 Financial Results on April 30, 2020 Business Wire
Apr-08-20 09:59AM  3 Blue-Chip Biotech Stocks Hitting New Highs Investopedia
08:00AM  Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference Business Wire
Apr-07-20 08:29AM  Amazon, Vertex Lead 5 Top Stocks Entering Buy Zones Investor's Business Daily
Apr-03-20 12:06PM  Seattle Genetics Issue Update on Padcev Label Expansion Study Zacks
Apr-02-20 04:44PM  Stock Indexes Jump As Jobless Claims Soar Again Investor's Business Daily +6.68%
04:37PM  Biotech Nears A Breakout As FDA Mulls Speedy Approval For Cancer Drug Investor's Business Daily
11:04AM  Seattle Genetics Nears Buy Point Investor's Business Daily Video
08:00AM  Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer Business Wire
Mar-17-20 05:54PM  Hedge Funds Have Never Been This Bullish On Seattle Genetics, Inc. (SGEN) Insider Monkey +5.20%
08:59AM  Is There An Opportunity With Seattle Genetics, Inc.'s (NASDAQ:SGEN) 46% Undervaluation? Simply Wall St.
Mar-10-20 08:00AM  Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference Business Wire
Mar-07-20 11:30AM  Why Is Seattle Genetics (SGEN) Down 3.2% Since Last Earnings Report? Zacks
Mar-02-20 08:00AM  Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-26-20 08:00AM  Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-19-20 05:12PM  Seattle Genetics bladder drug gets breakthrough therapy designation American City Business Journals
09:21AM  Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
08:28AM  Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer PR Newswire
08:12AM  Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer Business Wire
Feb-13-20 08:00AM  Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 08:00AM  Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer Business Wire
Feb-10-20 07:01PM  Edited Transcript of SGEN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
05:00PM  Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer PR Newswire
10:51AM  Seattle Genetics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
09:37AM  3 Nasdaq 100 Stocks With Excellent Upside Potential Investopedia
Feb-07-20 11:15AM  Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales Zacks
Feb-06-20 05:25PM  Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:07PM  Biotech Giant Crushes Sales Estimates And Posts A Profit But Shares Dive Investor's Business Daily
04:02PM  Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
02:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 09:45AM  Why Seattle Genetics (SGEN) Might Surprise This Earnings Season Zacks +6.09%
Jan-31-20 08:00AM  EMA Validates Seattle Genetics Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Jan-30-20 12:31PM  Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jan-21-20 06:13PM  Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe Zacks
08:30AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020 Business Wire
08:00AM  Seattle Genetics Achieves Milestone Following European Commission Approval of Roches Polivy® (Polatuzumab Vedotin) Business Wire
Jan-20-20 09:32AM  Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-16-20 08:56AM  How Much is Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Getting Paid? Simply Wall St.
Jan-09-20 04:24PM  How Did Seattle Genetics, Inc. (SGEN) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-06-20 08:00AM  Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-30-19 10:09AM  Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline Zacks
Dec-26-19 08:13PM  What could you have made by investing $1,000 in these Washington companies a decade ago? American City Business Journals
02:47PM  Tech will drive change in health care throughout next decade American City Business Journals
Dec-24-19 01:12PM  Seattle Genetics Submits NDA to FDA for Tucatinib Combo Zacks
Dec-23-19 08:00AM  Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-19-19 03:17PM  Seattle Genetics gets accelerated approval for cancer-killing drug American City Business Journals
12:02PM  Seattle Genetics' stock rises on approval of bladder cancer drug MarketWatch
11:35AM  Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug Zacks
10:37AM  Why This Leading Biotech Stock Just Added To Its 99% Gain This Year Investor's Business Daily
09:07AM  Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod Benzinga
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 07:49PM  FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer PR Newswire
06:42PM  Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval Business Wire
06:36PM  FDA Grants Accelerated Approval to Astellas and Seattle Genetics PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer Business Wire
08:00AM  Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-12-19 04:57PM  Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal GuruFocus.com
Dec-11-19 10:31AM  When Will Seattle Genetics, Inc. (NASDAQ:SGEN) Turn A Profit? Simply Wall St.
09:54AM  Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine Business Wire
Dec-09-19 10:00AM  Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting Business Wire
Dec-07-19 02:00PM  Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting Business Wire
08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 11:49AM  Hedge Funds Had Impeccable Timing Buying Seattle Genetics, Inc. (SGEN) Insider Monkey
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Dec-03-19 10:45AM  Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
Dec-02-19 09:21PM  This is what workers earn at some of Washington's largest public companies American City Business Journals
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorMay 15Sale160.001,750,000280,000,0004,082,851May 19 06:03 PM
ROMP CHARLES REVP, CommercialMay 12Option Exercise15.466,942107,32359,517May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 12Sale166.006,9421,152,37252,575May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 08Option Exercise15.466,942107,32359,517May 08 07:54 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.0028,472341,664728,603May 12 07:51 PM
SIEGALL CLAY BPresident and CEOMay 08Sale161.0128,4724,584,311718,339May 12 07:51 PM
BAKER BROS. ADVISORS LPDirectorMay 08Sale158.50500,00079,250,0004,230,539May 08 05:47 PM
ROMP CHARLES REVP, CommercialMay 08Sale163.026,9421,131,66752,575May 08 07:54 PM
DANSEY ROGER DChief Medical OfficerMay 07Option Exercise65.1111,912775,590129,145May 08 07:42 PM
DANSEY ROGER DChief Medical OfficerMay 07Sale164.5011,9121,959,526117,233May 08 07:42 PM
BAKER BROS. ADVISORS LPDirectorMay 07Sale164.41168,24427,660,9474,272,736May 08 05:47 PM
BAKER BROS. ADVISORS LPDirectorMay 06Sale165.05390,07264,379,4734,286,935May 08 05:47 PM
WELCH DANIEL GDirectorMay 06Sale164.7915,0002,471,91955,263May 07 07:59 PM
SIEGALL CLAY BPresident and CEOMay 06Sale165.2325,4024,197,062718,339May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Option Exercise22.1539,059865,277188,563May 06 06:32 PM
AKKARAJU SRINIVASDirectorMay 05Option Exercise20.068,500170,51048,668May 07 07:58 PM
SIEGALL CLAY BPresident and CEOMay 05Sale166.0824,5984,085,341743,741May 07 07:59 PM
WELCH DANIEL GDirectorMay 05Sale166.7320,0003,334,64170,263May 07 07:59 PM
AKKARAJU SRINIVASDirectorMay 05Sale167.268,5001,421,71040,168May 07 07:58 PM
ROMP CHARLES REVP, CommercialMay 05Sale166.185,056840,22652,575May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Sale162.9426,8674,377,596161,696May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Option Exercise12.0014,167170,004175,863May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Sale147.0014,1672,082,556161,696May 06 06:32 PM
LIPPMAN MARC EDirectorMay 04Sale152.031,000152,030130,313May 06 06:19 PM
BAKER BROS. ADVISORS LPDirectorApr 23Option Exercise12.7635,000446,60045,860,149Apr 24 04:25 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.0028,472341,664779,866Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOApr 08Sale120.0128,4723,416,814758,784Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise12.0028,472341,664768,581Mar 11 06:51 PM
SIEGALL CLAY BPresident and CEOMar 09Sale110.0928,4723,134,578758,784Mar 11 06:51 PM
HIMES VAUGHN BChief Technical OfficerMar 06Option Exercise13.518,000108,117193,172Mar 10 08:12 PM
HIMES VAUGHN BChief Technical OfficerMar 06Sale114.918,000919,292188,674Mar 10 08:12 PM
DANSEY ROGER DChief Medical OfficerFeb 18Sale116.3335040,716107,659Feb 20 05:33 PM
SIEGALL CLAY BPresident and CEOFeb 10Option Exercise12.0028,472341,664768,723Feb 12 05:38 PM
SIEGALL CLAY BPresident and CEOFeb 10Sale114.6128,4723,263,110758,784Feb 12 05:38 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale108.5172778,887108,009Feb 05 06:08 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.0028,472341,664785,937Jan 10 07:08 PM
SIEGALL CLAY BPresident and CEOJan 08Sale111.3228,4723,169,433758,784Jan 10 07:08 PM
WELCH DANIEL GDirectorJan 07Option Exercise12.7617,500223,30090,263Jan 09 08:32 PM
DANSEY ROGER DChief Medical OfficerDec 16Sale114.072,000228,140101,146Dec 17 06:48 PM
SIEGALL CLAY BPresident and CEODec 09Option Exercise12.0028,472341,664773,011Dec 10 07:15 PM
SIEGALL CLAY BPresident and CEODec 09Sale114.5628,4723,261,641755,684Dec 10 07:15 PM
HIMES VAUGHN BChief Technical OfficerDec 06Option Exercise12.008,00096,000195,518Dec 10 07:14 PM
HIMES VAUGHN BChief Technical OfficerDec 06Sale117.168,000937,265187,518Dec 10 07:14 PM
DANSEY ROGER DChief Medical OfficerNov 25Option Exercise65.115,000325,550108,146Nov 27 05:32 PM
DANSEY ROGER DChief Medical OfficerNov 25Sale121.485,000607,388103,146Nov 27 05:32 PM
AKKARAJU SRINIVASDirectorNov 21Option Exercise19.0217,500332,85052,726Nov 22 06:35 PM
AKKARAJU SRINIVASDirectorNov 21Sale119.7817,5002,096,12040,168Nov 22 06:35 PM
DANSEY ROGER DChief Medical OfficerNov 18Option Exercise65.115,000325,550108,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Option Exercise15.8935,000556,150148,813Nov 20 06:41 PM
DANSEY ROGER DChief Medical OfficerNov 18Sale116.005,000580,000103,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Sale115.8035,0004,053,000131,313Nov 20 06:41 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.0028,472341,664776,483Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEONov 08Sale107.6128,4723,063,816755,684Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.0028,472341,664770,104Oct 10 06:55 PM
SIEGALL CLAY BPresident and CEOOct 08Sale82.4728,4722,348,061755,684Oct 10 06:55 PM
GRYSKA DAVID WDirectorOct 01Option Exercise15.895,00079,45050,513Oct 03 07:38 PM
GRYSKA DAVID WDirectorOct 01Sale85.095,000425,45048,013Oct 03 07:38 PM
SIMPSON TODD EChief Financial OfficerSep 30Sale85.0015,0001,275,000157,567Oct 02 06:12 PM
LIU JEAN IGC/EVP, Leg AffairsSep 30Sale86.007,432639,15270,688Oct 02 06:10 PM
DANSEY ROGER DChief Medical OfficerSep 25Sale73.803,000221,415103,146Sep 27 06:12 PM
SIEGALL CLAY BPresident and CEOSep 09Option Exercise12.0028,472341,664774,374Sep 10 07:29 PM
SIEGALL CLAY BPresident and CEOSep 09Sale68.3328,4721,945,531755,684Sep 10 07:29 PM
HIMES VAUGHN BSee RemarksSep 03Sale70.805,692402,990187,518Sep 04 09:45 PM
SIEGALL CLAY BSee RemarksSep 03Sale70.809,693686,257755,684Sep 04 09:46 PM
DANSEY ROGER DSee RemarksSep 03Sale70.8092265,277106,146Sep 04 09:43 PM
SIMPSON TODD ESee RemarksSep 03Sale70.802,092148,112172,567Sep 04 09:42 PM
HIMES VAUGHN BSee RemarksAug 30Option Exercise12.008,00096,000201,210Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Sale72.868,000582,859193,210Sep 04 09:45 PM
LIU JEAN IGC/EVP, Leg AffairsAug 28Sale73.226,013440,24260,904Aug 30 04:35 PM
SIEGALL CLAY BPresident and CEOAug 28Sale73.2128,9512,119,636717,343Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale73.215,909432,624153,371Aug 30 04:36 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale73.216,836500,496175,197Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 20Sale80.0012,5001,000,000159,280Aug 22 05:49 PM
LIU JEAN IGC/EVP, Leg AffairsAug 20Sale80.003,716297,28066,917Aug 22 05:47 PM
SIEGALL CLAY BPresident and CEOAug 08Option Exercise12.1620,149245,012756,192Aug 09 05:06 PM
SIEGALL CLAY BPresident and CEOAug 08Sale76.5220,1491,541,827746,294Aug 09 05:06 PM
LIU JEAN IGC/EVP, Leg AffairsAug 06Sale75.003,716278,70070,633Aug 08 05:42 PM
GRYSKA DAVID WDirectorJul 17Option Exercise12.765,00063,80053,013Jul 19 06:20 PM
GRYSKA DAVID WDirectorJul 17Sale75.005,000375,00048,013Jul 19 06:20 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.1620,148245,000761,011Jul 10 06:57 PM
SIEGALL CLAY BPresident and CEOJul 08Sale66.8920,1481,347,664746,294Jul 10 06:57 PM
HIMES VAUGHN BChief Technical OfficerJun 24Option Exercise42.514,704199,970182,033Jun 26 06:26 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale68.605,416371,53877,593Jun 19 06:43 PM
SIEGALL CLAY BPresident and CEOJun 10Option Exercise12.1620,148245,000760,119Jun 12 05:51 PM
SIEGALL CLAY BPresident and CEOJun 10Sale69.0520,1481,391,175749,169Jun 12 05:51 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.008,00096,000185,329Jun 04 06:28 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale65.948,000527,485177,329Jun 04 06:28 PM